Saturday, 31 October 2026European Markets

ERAMET And ROBERTET Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - eramet (era.pa) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
eramet (era.pa) €82.40 3.94% 51.96%
robertet (rbt.pa) €845.00 0.96% 15.94%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eramet (era.pa)

3.94% forward dividend yield and 51.96% return on equity

eramet s.a. operates as a mining and metallurgical company in france, asia, europe, north america, and internationally. the company extracts and processes manganese ore and nickel ore; and extracts and develops mineral sands. it also produces ferronickel, nickel pig iron, briquettes, nickel salts, high purity nickel, nickel ferroalloys, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, pigments, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. in addition, it operates moanda mine in gabon; nickel mines in new caledonia and indonesia; and mineral sand mine in senegal and argentina. eramet s.a. was incorporated in 1880 and is headquartered in paris, france.

earnings per share

as for profitability, eramet has a trailing twelve months eps of €31.63.

pe ratio

eramet has a trailing twelve months price to earnings ratio of 2.61. meaning, the purchaser of the share is investing €2.61 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.96%.

revenue growth

year-on-year quarterly revenue growth grew by 10.3%, now sitting on 5.1b for the twelve trailing months.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 3, 2022, the estimated forward annual dividend rate is 3.5 and the estimated forward annual dividend yield is 3.94%.

yearly top and bottom value

eramet's stock is valued at €82.40 at 02:30 est, way under its 52-week high of €148.90 and way higher than its 52-week low of €60.60.

more news about eramet.

2. robertet (rbt.pa)

0.96% forward dividend yield and 15.94% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in three segments: raw materials, fragrances, and flavors. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €36.98.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 22.85. meaning, the purchaser of the share is investing €22.85 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.94%.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com